Neumora Therapeutics Inc (NASDAQ:NMRA) has a beta value of 2.52 and has seen 0.49 million shares traded in the recent trading session. The company, currently valued at $265.77M, closed the recent trade at $1.64 per share which meant it lost -$0.09 on the day or -4.91% during that session. The NMRA stock price is -1180.49% off its 52-week high price of $21.00 and 2.44% above the 52-week low of $1.60.
The consensus among analysts is that Neumora Therapeutics Inc (NMRA) is Buy stock at the moment, with a recommendation rating of 1.44. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.41.
Neumora Therapeutics Inc (NASDAQ:NMRA) trade information
Sporting -4.91% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the NMRA stock price touched $1.64 or saw a rise of 8.64%. Year-to-date, Neumora Therapeutics Inc shares have moved -84.48%, while the 5-day performance has seen it change -1.50%. Over the past 30 days, the shares of Neumora Therapeutics Inc (NASDAQ:NMRA) have changed -19.76%.
Wall Street analysts have a consensus price target for the stock at $4, which means that the shares’ value could jump 59.0% from the levels at last check today. The projected low price target is $4.0 while the price target rests at a high of $4.0. In that case, then, we find that the latest price level in today’s session is -143.9% off the targeted high while a plunge would see the stock gain -143.9% from the levels at last check today.
Neumora Therapeutics Inc (NMRA) estimates and forecasts
The company’s shares have lost -85.40% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%. Earnings growth for 2025 is a modest 56.61% while over the next 5 years, the company’s earnings are expected to increase by 24.06%.
NMRA Dividends
Neumora Therapeutics Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Neumora Therapeutics Inc (NASDAQ:NMRA)’s Major holders
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Sep 30, 2024, the former fund manager holds about 1.48% shares in the company for having 2.39 shares of worth $3.94 million while later fund manager owns 2.35 shares of worth $3.86 million as of Nov 30, 2024, which makes it owner of about 1.45% of company’s outstanding stock.
